MXPA05008802A - Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5. - Google Patents
Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5.Info
- Publication number
- MXPA05008802A MXPA05008802A MXPA05008802A MXPA05008802A MXPA05008802A MX PA05008802 A MXPA05008802 A MX PA05008802A MX PA05008802 A MXPA05008802 A MX PA05008802A MX PA05008802 A MXPA05008802 A MX PA05008802A MX PA05008802 A MXPA05008802 A MX PA05008802A
- Authority
- MX
- Mexico
- Prior art keywords
- urotensin
- somatostatin
- cyclopropanes
- benzothiazepines
- pyrazolines
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title abstract 2
- 108010056088 Somatostatin Proteins 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 229960000553 somatostatin Drugs 0.000 title abstract 2
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 title abstract 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 title 1
- 150000007657 benzothiazepines Chemical class 0.000 title 1
- 150000001942 cyclopropanes Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000003219 pyrazolines Chemical class 0.000 title 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000012327 Urotensin II receptors Human genes 0.000 abstract 2
- 108050002984 Urotensin II receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000050488 Urotensin II Human genes 0.000 abstract 1
- 108010018369 Urotensin II Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000013507 mapping Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C225/18—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings the carbon skeleton containing also rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invencion proporciona un procedimiento combinatorio para una biblioteca de nuevos compuestos que tienen cuatro puntos de diversidad. Los compuestos proporcionan la representacion de los receptores de urotensina II y somatostatina 5 mediante el enlace diferencial de dichos receptores. La presente invencion se refiere ademas a un metodo para tratar enfermedades para las cuales la modulacion de los receptores de urotensina II produce una respuesta fisiologicamente benefica en dicha enfermedad, tal como aquellas asociadas con la funcion del SNC y enfermedades cardiovasculares. La presente invencion se refiere ademas a composiciones farmaceuticas que comprenden estos agentes para el tratamiento de esas enfermedades adaptadas para modular al receptor de urotensina II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44862903P | 2003-02-19 | 2003-02-19 | |
| PCT/US2004/004765 WO2004073642A2 (en) | 2003-02-19 | 2004-02-18 | 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin ii and somatostatin 5 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008802A true MXPA05008802A (es) | 2005-10-18 |
Family
ID=32908620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008802A MXPA05008802A (es) | 2003-02-19 | 2004-02-18 | Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100029612A1 (es) |
| EP (1) | EP1638946A2 (es) |
| JP (1) | JP2006520328A (es) |
| KR (1) | KR20050100695A (es) |
| CN (1) | CN1751029A (es) |
| AU (1) | AU2004213000A1 (es) |
| BR (1) | BRPI0407651A (es) |
| CA (1) | CA2515706A1 (es) |
| MX (1) | MXPA05008802A (es) |
| RU (1) | RU2005129099A (es) |
| WO (1) | WO2004073642A2 (es) |
| ZA (1) | ZA200506625B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2970651B1 (fr) | 2011-01-25 | 2013-03-01 | Ct Hospitalier Universitaire Rouen | Urotensine ii et agonistes du recepteur de l'urotensine ii pour utilisation dans le traitement symptomatique du choc septique |
| JP6379805B2 (ja) * | 2013-09-17 | 2018-08-29 | 株式会社リコー | 情報処理プログラム、情報処理装置および情報処理システム |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2683742A (en) * | 1951-02-23 | 1954-07-13 | Searle & Co | Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives |
| US2793212A (en) * | 1953-12-09 | 1957-05-21 | Lilly Co Eli | Substituted benzamidopiperidinopropanes |
| US3096329A (en) * | 1957-10-15 | 1963-07-02 | Sterling Drug Inc | Triazolo [b] pyridazines |
| GB1143702A (es) * | 1965-03-18 | |||
| US3401166A (en) * | 1966-08-01 | 1968-09-10 | Squibb & Sons Inc | Therapeutically active benzothiazines |
| US3880885A (en) * | 1971-11-23 | 1975-04-29 | Sandoz Ag | Tertiary aminoethyl isochromans and isocoumarins |
| DE3243518A1 (de) * | 1982-11-25 | 1984-05-30 | Basf Ag, 6700 Ludwigshafen | Substituierte 1-oxo-2-phenyl-2-(2-alkylaminoethyl)-1,2,3,4- tetrahydronaphthaline, ihre herstellung und verwendung |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
-
2004
- 2004-02-18 KR KR1020057015324A patent/KR20050100695A/ko not_active Application Discontinuation
- 2004-02-18 BR BRPI0407651-6A patent/BRPI0407651A/pt not_active IP Right Cessation
- 2004-02-18 US US10/568,149 patent/US20100029612A1/en not_active Abandoned
- 2004-02-18 CN CNA2004800046476A patent/CN1751029A/zh active Pending
- 2004-02-18 JP JP2006503667A patent/JP2006520328A/ja not_active Withdrawn
- 2004-02-18 MX MXPA05008802A patent/MXPA05008802A/es not_active Application Discontinuation
- 2004-02-18 AU AU2004213000A patent/AU2004213000A1/en not_active Abandoned
- 2004-02-18 RU RU2005129099/04A patent/RU2005129099A/ru not_active Application Discontinuation
- 2004-02-18 EP EP04712329A patent/EP1638946A2/en not_active Withdrawn
- 2004-02-18 WO PCT/US2004/004765 patent/WO2004073642A2/en active Application Filing
- 2004-02-18 CA CA002515706A patent/CA2515706A1/en not_active Abandoned
-
2005
- 2005-08-18 ZA ZA200506625A patent/ZA200506625B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1751029A (zh) | 2006-03-22 |
| EP1638946A2 (en) | 2006-03-29 |
| AU2004213000A1 (en) | 2004-09-02 |
| KR20050100695A (ko) | 2005-10-19 |
| BRPI0407651A (pt) | 2006-02-21 |
| ZA200506625B (en) | 2006-08-30 |
| JP2006520328A (ja) | 2006-09-07 |
| RU2005129099A (ru) | 2006-04-20 |
| WO2004073642A3 (en) | 2005-03-17 |
| US20100029612A1 (en) | 2010-02-04 |
| CA2515706A1 (en) | 2004-09-02 |
| WO2004073642A2 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ516599A (en) | 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands | |
| GEP20074197B (en) | 5ht2c receptor modulators | |
| EP1423370A4 (en) | COMPOUNDS BINDING TO THE NUCLEAR FXR-NR1H4 RECEPTOR | |
| IL192605A0 (en) | 1,2-dihydropyridin-2-one derivatives and pharmaceutical compositions containing the same | |
| BRPI0407454A (pt) | Pirazóis e métodos de preparar e usar os mesmos | |
| DK1054887T3 (da) | Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister | |
| WO2002089738A3 (en) | Proteomimetic compounds and methods | |
| EP1590336A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
| EA200501236A1 (ru) | Аминогетероарильные соединения в качестве ингибиторов протеинкиназ | |
| DE60131730D1 (de) | Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden | |
| TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
| MY133406A (en) | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament | |
| MXPA02009773A (es) | Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina. | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| DK1551803T3 (da) | Azabicycloderivater som muskarine receptorantagonister | |
| DE60226906D1 (de) | 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen | |
| CO5460266A1 (es) | Novedosos analogos de la somatostatina | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| MXPA05008802A (es) | Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5. | |
| NO20014961L (no) | Integrin-reseptor-ligander | |
| ATE529114T1 (de) | Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors | |
| ATE448223T1 (de) | 8-azabicycloä3.2.1üoctanderivate und ihre verwendung als monoamine-neurotransmitter- reuptake inhibitoren | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
| ATE359263T1 (de) | Substitutierte aminosaeuren als erythropoietin- mimetica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |